Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tunlametinib + nimotuzumab
- Development stage
- Unknown
- Lead developer
- Shanghai KeChow Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Tunlametinib + nimotuzumab is a combination therapy being evaluated for the treatment of RAS-mutated advanced gastrointestinal malignancies, specifically pancreatic cancer. Tunlametinib (HL-085) is a potent and selective small molecule inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2), which are key components of the MAPK/ERK signaling pathway often dysregulated in RAS-mutated cancers. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), blocking ligand binding and downstream signaling. The combination is designed to achieve dual inhibition of the EGFR and MEK pathways to overcome resistance and enhance anti-tumor efficacy. This specific combination is being investigated in a Phase 2 clinical trial sponsored by the Chinese PLA General Hospital.
- Other names
- tunlametinib + nimotuzumab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on tunlametinib + nimotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tunlametinib + nimotuzumab.